永勤集團控股(08275.HK)擬“5合1”並股及“2供3”供股
格隆匯1月14日丨永勤集團控股(08275.HK)公吿,公司建議進行股份合併,擬“5合1”合併股份。
公司建議按於記錄日期每持有2股合併股份獲發3股供股股份的基準,以認購價每股供股股份0.55港元進行供股,透過向合資格股東發行8100萬股供股股份籌集約4460萬港元。
公司擬將建議供股所得款項淨額(i)約310萬港元用於償還承兑票據的本金及應計利息;(ii)因現有辦公物業的租約將於2022年4月屆滿,約2000萬港元用於購置新辦公物業及相關裝修費用;(iii)約700萬港元用於增聘全職員工;(iv)約300萬港元用於發展業務及營銷開支;及(v)餘額約950萬港元撥充一般營運資金。i
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.